A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3503 participants.

Also called NCT02145468

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,503 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02145468
Other papers using this trial's data
  • Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial JAMA, 2016-04-19 DOI, PubMed 27043082

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02145468. Randomized; double masking; primary purpose treatment. Start 2014-06-03 (actual); primary completion 2015-12-14 (actual). Results posted on 2017-06-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Acronym
LATITUDE
Condition
Acute Coronary Syndrome
Intervention (Drug)
Losmapimod 7.5 mg twice daily
Intervention (Drug)
Placebo twice daily
Intervention (Drug)
Standard therapy
Lead sponsor
GlaxoSmithKline (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct02145468
Content hash
015679438d4f6437ebab028f1dd90129fb41c3bfec8bae1c512fed129da0d8d6